-+ 0.00%
-+ 0.00%
-+ 0.00%

CORE BIOMEDICINE: CO OBTAINED EXCLUSIVE, GLOBAL RIGHTS TO CERTAIN PRECLINICAL ONCOLOGY PROGRAMS THAT TARGET KEY MOLECULAR DRIVERS OF VARIOUS CANCERS

路透·07/28/2026 12:22:08

登錄查看新聞詳情